EndoGastric funds US sales with $30m round:
This article was originally published in Clinica
Executive Summary
Natural orifice surgery (NOS) specialist EndoGastric Solutions has completed a $30m series D round of financing. Redmond, Washington-based EndoGastric plans to use the new finances to expand sales and marketing efforts for its transoral StomaphyX device for binding tissue in the gastrointestinal tract to help weight loss, and fund the launch of its EsophyX device for treating gastroesophageal reflex disease later this year. The round was lead by DeNovo Ventures and included contributions from existing investors Chicago Growth Partners, MPM Capital, Advanced Technology Ventures, Foundation Medical Partners and Oakwood Medical Investors. The financing sees DeNovo's Joe Mandato join the EndoGastric board of directors.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.